1. Home
  2. Labeler Index
  3. Avenacy, Inc.
  4. 83634-203
  5. Product Images: Fulvestrant

Product Images Fulvestrant

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Figure 1 - ful0c 0000 01
  2. Figure 2 - ful0c 0000 02
  3. Figure 3 - ful0c 0000 03
  4. Figure 4 - ful0c 0000 04
  5. Figure 5 - ful0c 0000 05
  6. Structural Formula - ful0c 0000 06
  7. Figure 6 - ful0c 0000 07
  8. Figure 7 - ful0c 0000 08
  9. Figure 8 - ful0c 0000 09
  10. Figure 9 - ful0c 0000 10
  11. Figure 10 - ful0c 0000 11
  12. Figure 11 - ful0c 0000 12
  13. Figure 12 - ful0c 0000 13
  14. Figure 13 - ful0c 0000 14
  15. Figure 14 - ful0c 0000 15
  16. PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Syringe Label - ful0c 0000 16

Product Label Images

The following 16 images provide visual information about the product associated with Fulvestrant NDC 83634-203 by Avenacy, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - ful0c 0000 01

Figure 1 - ful0c 0000 01

Figure 2 - ful0c 0000 02

Figure 2 - ful0c 0000 02

Figure 3 - ful0c 0000 03

Figure 3 - ful0c 0000 03

Figure 4 - ful0c 0000 04

Figure 4 - ful0c 0000 04

Figure 5 - ful0c 0000 05

Figure 5 - ful0c 0000 05

Structural Formula - ful0c 0000 06

Structural Formula - ful0c 0000 06

Figure 6 - ful0c 0000 07

Figure 6 - ful0c 0000 07

This is a presentation of Progression-Free Survival (ITT Population) data for Fulvestrant 250mg and 500mg over a period of 45 months. The graph shows the number at risk at various time points for both doses of Fulvestrant. The data allows for an analysis of the effectiveness of each dose in terms of maintaining progression-free survival over time.*

Figure 7 - ful0c 0000 08

Figure 7 - ful0c 0000 08

Figure 8 - ful0c 0000 09

Figure 8 - ful0c 0000 09

Figure 9 - ful0c 0000 10

Figure 9 - ful0c 0000 10

Figure 10 - ful0c 0000 11

Figure 10 - ful0c 0000 11

This is a survival probability chart showing the number of patients at risk over time for different treatment groups. The text provides information on two treatment groups: fulvestrant with palbociclib and fulvestrant with placebo. The number of patients at risk in each group is shown at various time points from 12 to 48 months. Additionally, the abbreviations FUL, PAL, and PCB are defined as fulvestrant, palbociclib, and placebo, respectively.*

Figure 11 - ful0c 0000 12

Figure 11 - ful0c 0000 12

Figure 12 - ful0c 0000 13

Figure 12 - ful0c 0000 13

Figure 13 - ful0c 0000 14

Figure 13 - ful0c 0000 14

Figure 14 - ful0c 0000 15

Figure 14 - ful0c 0000 15

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Syringe Label - ful0c 0000 16

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Syringe Label - ful0c 0000 16

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.